International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 1 , Pages 14-22 , January 2010

Long-Term Toxicity Following 3D Conformal Radiation Therapy for Prostate Cancer From the RTOG 9406 Phase I/II Dose Escalation Study

Presented at the Annual Meeting of the American Urological Association, Anaheim, CA, May 19–24, 2007.

  • Jeff M. Michalski, M.D.

      Affiliations

    • Radiation Oncology, Washington University Medical School, St. Louis, MO
    • Corresponding Author InformationReprint requests to: Jeff M. Michalski, M.D., Department of Radiation Oncology, Washington University School of Medicine, 4921 Parkview Place, Campus box 8224, St. Louis, MO 63110. Tel: (314) 362-28566; Fax: (314) 747-9557
    • ,
  • Kyounghwa Bae, Ph.D.

      Affiliations

    • Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, PA
    • ,
  • Mack Roach, M.D.

      Affiliations

    • Radiation Oncology, University of California-San Francisco, San Francisco, CA
    • ,
  • Arnold M. Markoe, M.D.

      Affiliations

    • Radiation Oncology, University Miami, Miami, FL
    • ,
  • Howard M. Sandler, M.D.

      Affiliations

    • Radiation Oncology, University of Michigan, Ann Arbor, MI
    • ,
  • Janice Ryu, M.D.

      Affiliations

    • Radiation Oncology, University of California-Davis, Davis, CA
    • ,
  • Matthew B. Parliament, M.D.

      Affiliations

    • Radiation Oncology, University of Alberta, Edmonton, AL, Canada
    • ,
  • William Straube, M.S.

      Affiliations

    • Image-guided Therapy Center, St. Louis, MO
    • ,
  • Richard K. Valicenti, M.D.

      Affiliations

    • Radiation Oncology, Thomas Jefferson University, Philadelphia, PA
    • ,
  • James D. Cox, M.D.

      Affiliations

    • Radiation Oncology, MD Anderson Cancer Center, Houston, TX

Received 25 September 2008 ,Revised 6 January 2009 ,Accepted 26 January 2009.

References 

  1. Michalski J, Purdy JA, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 2000;46:391–402
  2. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys. 2005;62:706–713
  3. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys. 2004;58:735–742
  4. In:  Beahrs O,  Henson D,  Hutter R, et al. editor. AJCC cancer staging manual. 4th ed. Philadelphia: Lippincott-Raven; 1992;
  5. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 2002;54:1036–1046
  6. International Commission on Radiation Units and Measurement. ICRU Report 50. Prescribing, recording, and reporting photon beam therapy. Bethesda, MD: ICRU; 1993;
  7. Diaz A, Roach M, Marquez C, et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;30:323–329
  8. Roach M. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:1923–1924
  9. Lee WR, Hanks GE, Hanlon AL, et al. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys. 1996;35:251–257
  10. Cox DR. Regression models and life tables. J Royal Stat Soc B. 1972;34:187–229
  11. Bonferroni CE. Teoria statistica delle classi e calcolo delle probabailit [Statistic theory of the classes and probability calculus.]. Pubblicazioni del R Istituto Superiore di Scienze Economiche di Firenze 1936;8:3–62.
  12. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  13. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996
  14. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487
  15. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–1239
  16. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–1129
  17. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  18. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  19. King CR, Fowler JF. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys. 2001;51:213–214
  20. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68:1424–1430
  21. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099–1105

 This article was supported by grants RTOG U10 CA21661, CCOP U10 CA37422, Stat U10 CA32115, and ITC U24 CA081647 from the National Cancer Institute.

 Conflict of interest: none.

PII: S0360-3016(09)00210-7

doi: 10.1016/j.ijrobp.2009.01.062

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 1 , Pages 14-22 , January 2010

Article Tools

* Image Usage & Resolution